Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

NCT04508530 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT04508530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Superiority Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Lead sponsor
Octapharma
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2021
Completion date
October 30, 2024
Enrollment
71 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric acute-onset neuropsychiatric syndrome